Slideset1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Long-Acting Injectable Formulation of Ivermectin as a New Vector Control Tool to Reduce Malaria Transmission - Quiterie Savary de BeauregardView Slideset
VideoViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #4 Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results - Yasmin IbrahimView Video
SlidesetViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #4 Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results - Yasmin IbrahimView Slideset
VideoHIVTuberculosisViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna GaayebView Video
SlidesetHIVTuberculosisViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna GaayebView Slideset
VideoHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Video
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Slideset
VideoTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Video
SlidesetTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Slideset
VideoTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Video
SlidesetTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Slideset
VideoNTDTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina KovarovaView Video
